Form 4 for ANGO ANGIODYNAMICS INC
Accepted 2024-08-02 00:00:00 ET · period of report 2024-07-17 · accession 0001140361-24-035600 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-02 | 2024-07-17 | ANGO | Clemmer James C | Pres, CEO, Dir | F - Tax | $7.40 | -28.7K | 661.6K | -4% | -$212.6K |
| D | 2024-08-02 | 2024-07-17 | ANGO | Clemmer James C | Pres, CEO, Dir | M - OptEx | $0.00 | +56.3K | 690.3K | +9% | $0 |
| D | 2024-08-02 | 2024-07-17 | ANGO | Clemmer James C | Pres, CEO, Dir | M - OptEx | $0.00 | +52.4K | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-17 | F | D | 28,730 | $7.40 | 661,582 | D | — | — | (F2) The exempt disposition of 28,730 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021. |
| 2 | Common | Common Stock | 2024-07-17 | M | A | 56,279 | $0.00 | 690,312 | D | — | — | (F1) This acquisition of 56,279 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021. |
| 3 | Derivative | Performance Right | 2024-07-17 | M | A | 52,378 | $0.00 | 0 | D | — · — to — | 52,378 Common Stock | (F3) On July 21, 2021, the reporting person received a target grant of 52,378 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 56,279 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited. |